ERBB2 and ductal breast carcinoma in situ: Administration of class II HER2 peptide-pulsed Type I polarized dendritic cell (DC1) vaccine induced a strong anti-HER2 immune response with pathologic complete response rate (pCR) in HER2+ DCIS patients (29–31).